The FDA will hold a public meeting July 9 to allow adult and pediatric patients to give the agency their perspectives on the effects of chronic pain, treatment approaches for chronic pain and barriers to accessing treatments.
The FDA is particularly interested in hearing the perspectives of patients who manage chronic pain with opioids, acetaminophen, nonsteroidal anti-inflammatory drugs, antidepressants as well as non-pharmacologic therapies.
The agency is considering guidelines for physicians to encourage "more rational" prescribing, FDA Commissioner Scott Gottlieb, MD, wrote in a blog post May 14.
"For example, one idea the FDA is considering is the development of a strategy for encouraging medical professional societies to develop evidence-based guidelines on appropriate prescribing for different acute medical indications," Dr. Gottlieb said.
The July 9 meeting will be held from 10 a.m. to 4 p.m. at the FDA's White Oak Campus in Silver Spring, Md. People can submit electronic or written comments on this public workshop by Sept. 10.
For more information on the meeting, click here.